News News March, 2020 IGM Biosciences to Present at Two Upcoming Investor Conferences Read More... February, 2020 IGM Biosciences to Present at Two Upcoming Investor Conferences Read More... January, 2020 IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis Read More... November, 2019 A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions Read More... November, 2019 IGM Biosciences to Present at Three Upcoming Investor Conferences Read More... November, 2019 IGM Biosciences Announces Third Quarter 2019 Financial Results Read More... October, 2019 IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma Read More... September, 2019 IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Read More... September, 2019 IGM Biosciences Announces Pricing of Initial Public Offering Read More... July, 2019 IGM Biosciences Announces $102 Million Series C Financing to Advance its IgM Antibody Platform and Pipeline Read More... « Previous 1 2 3 4 5 Next »
